文献速递白血病

Vibecotamab治疗复发/难治性急性髓系白血病的1期研究确定优化剂量

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

这项1期研究评估了CD3/CD123双特异性抗体vibecotamab单药治疗复发/难治性急性髓系白血病的安全性和耐受性,并确定最大耐受剂量/推荐剂量。采用3次递增剂量(第1周)后每周给药方案可减少细胞因子释放综合征。120例中16例至少1起治疗中出现的不良事件被归类为剂量限制性毒性,细胞因子释放综合征最常见(59.2%),大多≤2级。111例可评估疗效的AML患者中10例(9.0%)达到形态学无白血病状态或更好,总客观缓解率为9.0%;仅在目标剂量≥0.75 μg/kg的患者(n=87)中观察到缓解,该组可评估疗效的客观缓解率为11.5%。

要点

  • 3次递增剂量(第1周)后每周给药方案可减少细胞因子释放综合征。
  • 细胞因子释放综合征最常见(59.2%),经预给药管理后大多≤2级。
  • 目标剂量≥0.75 μg/kg组可评估疗效的客观缓解率为11.5%,总客观缓解率为9.0%。

核心结论

  • Vibecotamab单药治疗复发/难治性AML的推荐2期剂量方案为第1周3次递增剂量后每周给药(1.7 μg/kg,队列-1D)。
  • 缓解仅在目标剂量≥0.75 μg/kg的患者中观察到,且与血液和骨髓中较低的基线原始细胞计数(<25%)相关,提示潜在获益。

研究设计与样本

  • 1期研究,主要目标为安全性和耐受性以及确定单药治疗复发/难治性AML的最大耐受剂量/推荐剂量。
  • 共120例患者纳入安全性分析,111例AML患者可评估疗效。
  • 试验注册号NCT02730312。

主要发现

  • 120例中16例至少1起治疗中出现的不良事件被归类为剂量限制性毒性。
  • 细胞因子释放综合征为最常见不良事件(59.2%),经预给药管理后大多≤2级。
  • 111例可评估疗效的AML患者中10例(9.0%)达到形态学无白血病状态或更好,总客观缓解率为9.0%。
  • 目标剂量≥0.75 μg/kg的患者(n=87)中可评估疗效的客观缓解率为11.5%。
  • 缓解与血液和骨髓中较低的基线原始细胞计数(<25%)相关。

关键数值与推荐

  • 推荐2期剂量方案:第1周3次递增剂量后每周给药(1.7 μg/kg,队列-1D)。
  • 目标剂量≥0.75 μg/kg(n=87)可评估疗效的客观缓解率为11.5%。
  • 总客观缓解率为9.0%(10/111)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study's primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ravandi F, Bashey A, Foran J, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023. PMID: 37647601. doi:10.1182/bloodadvances.2023010956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。